Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Chief Financial Officer | April 22, 2020 | April 24, 2020 |
| C4 Therapeutics, Inc.CCCC · Entity 5503 | Director · President & CEO | February 13, 2026 | February 18, 2026 |
| Editas Medicine, Inc.EDIT · Entity 5502 | Director | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date April 22, 2020 · Filed April 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 24,272 |
Ending reported balance
After 2020-04-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-04-22 · Exercise / conversion · Acquired 5,893 · Balance 26,199 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Row 2 · 2020-04-22 · Tax withholding · Disposed 1,927 · Balance 24,272 |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 11,785 |
Reported balance
After 2020-04-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-04-22 · Exercise / conversion · Disposed 5,893 · Balance 11,785 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on April 22, 2019. Beginning on April 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: The restricted stock units were granted on April 22, 2019. Beginning on April 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
C4 Therapeutics, Inc.
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,123,145 |
Reported balance
After 2026-02-13 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-02-13 · Grant · Acquired 700,000 · Balance 1,123,145 F1: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 350,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 350,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones. |
| Common StockSEC Table I · non-derivative | Direct | 1,123,145 |
Reported balance
After 2026-02-14 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-02-14 · Exercise / conversion · Acquired 81,725 · Balance 1,123,145 F2: Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 15, 2024 and February 18, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 1,083,991 |
Reported balance
After 2026-02-14 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-02-14 · Tax withholding · Disposed 39,154 · Balance 1,083,991 F3: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. |
| Common StockSEC Table I · non-derivative | Direct | 1,083,991 |
Reported balance
After 2026-02-15 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-02-15 · Exercise / conversion · Acquired 20,400 · Balance 1,083,991 F2: Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 15, 2024 and February 18, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 1,074,934 |
Reported balance
After 2026-02-15 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2026-02-15 · Tax withholding · Disposed 9,057 · Balance 1,074,934 F3: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 350,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 350,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
F2: Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 15, 2024 and February 18, 2025.
F3: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Editas Medicine, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2036-06-16 | Direct | 51,700 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 51,700 · Balance 51,700 F1: This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 20:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 51,700 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001650664-26-000070 · wk-form4_1782160207.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,700 Underlying: Common Stock · 51,700 shares Expires 2036-06-16 F1 · derivative.exercise_date: This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 22:04 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 9,057 | $1.89 | $17,117.73 |
DisclosureSEC source: 0001470831-26-000177 · wk-form4_1771452294.xml · nonDerivative · entry 5 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,074,934 F3 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 22:04 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 20,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000177 · wk-form4_1771452294.xml · nonDerivative · entry 4 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,083,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 15, 2024 and February 18, 2025. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:04 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 39,154 | $1.89 | $74,001.06 |
DisclosureSEC source: 0001470831-26-000177 · wk-form4_1771452294.xml · nonDerivative · entry 3 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,083,991 F3 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:04 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 81,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000177 · wk-form4_1771452294.xml · nonDerivative · entry 2 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,123,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 15, 2024 and February 18, 2025. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:04 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 700,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000177 · wk-form4_1771452294.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,123,145 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 350,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 350,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:18 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 37,500 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001650664-25-000099 · wk-form4_1749586673.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2035-06-05 F1 · derivative.exercise_date: This option was granted on June 6, 2025 and is scheduled to vest in full on June 6, 2026. Read SEC document |
| February 15, 2025 Filed Feb 18, 2025 21:55 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 9,370 | $3.18 | $29,796.60 |
DisclosureSEC source: 0001662579-25-000021 · wk-form4_1739915729.xml · nonDerivative · entry 3 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 423,145 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:55 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 335,300 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001662579-25-000021 · wk-form4_1739915729.xml · derivative · entry 4 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335,300 Underlying: Common Stock · 335,300 shares Expires 2035-02-13 F3 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in forty-eight equal monthly installments following the grant date, with the first installment vesting on March 14, 2025. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:55 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 12,847 | $3.18 | $40,853.46 |
DisclosureSEC source: 0001662579-25-000021 · wk-form4_1739915729.xml · nonDerivative · entry 2 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 432,515 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:55 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 223,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-25-000021 · wk-form4_1739915729.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 445,362 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2026. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 21:17 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000100 · wk-form4_1731446213.xml · derivative · entry 3 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 12,500 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 21:17 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 5,550 | $6.04 | $33,522.00 |
DisclosureSEC source: 0001662579-24-000100 · wk-form4_1731446213.xml · nonDerivative · entry 2 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,862 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 21:17 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-24-000100 · wk-form4_1731446213.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 21:12 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000084 · wk-form4_1726607560.xml · derivative · entry 3 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 7,500 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 21:12 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 3,329 | $6.36 | $21,172.44 |
DisclosureSEC source: 0001662579-24-000084 · wk-form4_1726607560.xml · nonDerivative · entry 2 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,912 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 21:12 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-24-000084 · wk-form4_1726607560.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 21:11 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.17 | $0.00 |
DisclosureSEC source: 0001650664-24-000068 · wk-form4_1717449062.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-05-29 F1 · derivative.exercise_date: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025. Read SEC document |
| February 15, 2024 Filed Feb 15, 2024 23:18 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 6,560 | $7.90 | $51,824.00 |
DisclosureSEC source: 0001662579-24-000022 · wk-form4_1708039090.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,741 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 22:08 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 465,500 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001662579-24-000020 · wk-form4_1708034921.xml · derivative · entry 2 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 465,500 Underlying: Common Stock · 465,500 shares Expires 2034-02-13 F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2024. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 22:08 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 103,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000020 · wk-form4_1708034921.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,301 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2025. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 23:24 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 489,600 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001662579-23-000102 · wk-form4_1695165874.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 489,600 Underlying: Common Stock · 489,600 shares Expires 2033-09-17 F1 · derivative.exercise_date: This option shall vest in full on September 18, 2025, subject to the Reporting Person's continued service on such date. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:13 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000086 · wk-form4_1693512793.xml · derivative · entry 3 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 7,500 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:13 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 2,205 | $2.93 | $6,460.65 |
DisclosureSEC source: 0001662579-23-000086 · wk-form4_1693512793.xml · nonDerivative · entry 2 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,901 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:13 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000086 · wk-form4_1693512793.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001415889-23-009231 · form4-06052023_040604.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-05-31 F1 · derivative.exercise_date: This option was granted on June 1, 2023 and is scheduled to vest in full on June 1, 2024. Read SEC document |
| February 15, 2023 Filed Feb 15, 2023 21:44 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 367,200 | $0.00 Strike: $5.77 | $0.00 |
DisclosureSEC source: 0001662579-23-000034 · wf-form4_167649743141884.xml · derivative · entry 2 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,200 Underlying: Common Stock · 367,200 shares Expires 2033-02-14 F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 15, 2023. Read SEC document |
| February 15, 2023 Filed Feb 15, 2023 21:44 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 81,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000034 · wf-form4_167649743141884.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,606 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 15, 2024. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:09 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000021 · wf-form4_167528577737212.xml · derivative · entry 3 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 12,500 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:09 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 4,319 | $7.78 | $33,601.82 |
DisclosureSEC source: 0001662579-23-000021 · wf-form4_167528577737212.xml · nonDerivative · entry 2 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,006 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:09 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000021 · wf-form4_167528577737212.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $12.31 | $0.00 |
DisclosureSEC source: 0001415889-22-006489 · form4-06132022_040606.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: This option was granted on June 9, 2022 and is scheduled to vest in full on June 9, 2023 Read SEC document |
| May 26, 2022 Filed Jun 14, 2022 20:45 UTC Amendment | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 3,675 | $7.01 | $25,761.75 |
DisclosureSEC source: 0001209191-22-036716 · doc4a.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,825 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of performance restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:15 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032508 · doc4.xml · derivative · entry 2 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 12,500 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:15 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-032508 · doc4.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| April 12, 2022 Filed Apr 12, 2022 20:05 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | PurchaseCommon Stock | 10,000 | $8.40 | $84,000.00 |
DisclosureSEC source: 0001209191-22-024130 · doc4.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| February 23, 2022 Filed Feb 23, 2022 21:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantPerformance Restricted Stock Units · Derivative | 87,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-012216 · doc4.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2025-02-28 F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 72,500 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 72,500 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:11 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 11,538 | $0.00 Strike: $33.36 | $0.00 |
DisclosureSEC source: 0001179110-21-006451 · edgar.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2031-06-02 F1 · derivative.exercise_date: This option was granted on June 3, 2021 and is scheduled to vest in full on June 3, 2022. Read SEC document |
| October 01, 2020 Filed Oct 6, 2020 01:00 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 1,691,672 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027448 · doc4.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,691,672 Underlying: Common Stock · 1,691,672 shares Expires 2030-09-30 F1 · derivative.exercise_date: 12.5% of this option shall vest and become exercisable on April 1, 2021, with the remainder vesting in 14 equal quarterly installments thereafter. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:18 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 11,538 | $0.00 Strike: $27.49 | $0.00 |
DisclosureSEC source: 0001179110-20-007273 · edgar.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2030-06-09 F1 · derivative.exercise_date: This option was granted on June 10, 2020 and is scheduled to vest in full on June 10, 2021. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 20:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 5,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000033 · wf-form4_158775877429935.xml · derivative · entry 3 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,785 Underlying: Common stock · 5,893 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on April 22, 2019. Beginning on April 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on April 22, 2019. Beginning on April 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 20:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 1,927 | $45.91 | $88,468.57 |
DisclosureSEC source: 0001439222-20-000033 · wf-form4_158775877429935.xml · nonDerivative · entry 2 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,272 Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 20:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 5,893 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001439222-20-000033 · wf-form4_158775877429935.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 20:26 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 1,599 | $40.64 | $64,983.36 |
DisclosureSEC source: 0001439222-20-000031 · wf-form4_158698238335139.xml · nonDerivative · entry 2 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,306 Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 20:26 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 5,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000031 · wf-form4_158698238335139.xml · derivative · entry 3 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,775 Underlying: Common stock · 5,387 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified commercial milestone was determined to have been met on April 13, 2020, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified commercial milestone was determined to have been met on April 13, 2020, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 20:26 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 5,387 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001439222-20-000031 · wf-form4_158698238335139.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 21:27 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 1,056 | $48.66 | $51,384.96 |
DisclosureSEC source: 0001439222-20-000024 · wf-form4_158266604156652.xml · nonDerivative · entry 2 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,518 Read SEC document |
| February 22, 2020 Filed Feb 25, 2020 21:27 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000024 · wf-form4_158266604156652.xml · derivative · entry 3 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common stock · 3,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 22, 2020 Filed Feb 25, 2020 21:27 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001439222-20-000024 · wf-form4_158266604156652.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:51 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 886 | $52.01 | $46,080.86 |
DisclosureSEC source: 0001439222-20-000016 · wf-form4_158214909552275.xml · nonDerivative · entry 2 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,241 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.